SCHEMBL7220992

SCHEMBL7220992

COc1cccc2c1C(C(=O)N1CC=C(c3c[nH]c4cc(Cl)ccc34)CC1)CC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.51
HTR1D P28221 1/20 0.43
LMNA P02545 1/20 0.42
SLC6A4 P31645 1/20 0.41
HTR1A P08908 1/20 0.40
POLB P06746 1/20 0.40
OPRL1 P41146 1/20 0.39
PLK4 O00444 1/20 0.38
CHEK1 O14757 1/20 0.38
AURKA O14965 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
CHEK2 O96017 1/20 0.38
PRKCG P05129 1/20 0.38
CDK1 P06493 1/20 0.38
RET P07949 1/20 0.38
PIM1 P11309 1/20 0.38
FGFR1 P11362 1/20 0.38
PRKACA P17612 1/20 0.38
RPS6KB1 P23443 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7214538 0.83 SLC6A4 (0.45) MAPTHTR1DLMNASLC6A4HTR1A
SCHEMBL7213855 0.80 HTR1A (0.48) HTR1DHTR1A
SCHEMBL7219966 0.78 MAPT (0.51) MAPTHTR1DLMNASLC6A4POLB
SCHEMBL6911179 0.76 SLC6A4 (0.46) MAPTHTR1DLMNASLC6A4HTR1A
SCHEMBL16801678 0.76 SLC6A4 (0.56) MAPTHTR1DLMNASLC6A4HTR1A
SCHEMBL7953809 0.75 MAPT (0.53) MAPTHTR1DLMNASLC6A4HTR1A
SCHEMBL28097371 0.74 MAPT (0.54) MAPTHTR1DLMNASLC6A4POLB
SCHEMBL7402960 0.73 MAPT (0.47) MAPTHTR1DLMNASLC6A4POLB
SCHEMBL7221082 0.73 MAPT (0.49) MAPTHTR1DLMNASLC6A4POLB
SCHEMBL7215851 0.73 MAPT (0.52) MAPTLMNASLC6A4HTR1APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552044-B2 Dopamine receptors H. LUNDBECK A/S (DK) 2003-04-22 US disclosed
EP-0946542-B1 INDANE OR DIHYDROINDOLE DERIVATIVES LUNDBECK & CO AS H (DK) 2002-10-09 EP disclosed
US-6352988-B2 HIGH AFFINITY FOR D4 RECEPTORS; TREATMENT OF SCHIZOPHRENIA, OTHER PSYCHOSES, ANXIETY DISORDERS, DEPRESSION, ALCOHOL ABUSE, IMPULSE CONTROL DISORDERS, AGGRESSION H. LUNDBECK A/S (DK) 2002-03-05 US disclosed
US-20010021777-A1 Indane or dihydroindole derivatives H. LUNDBECK A/S (DK) 2001-09-13 US disclosed
US-20010020095-A1 Indane or dihydroindole derivatives H. LUNDBECK A/S (DK) 2001-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010020095-A1 Indane or dihydroindole derivatives HTR4, GPR4, GPR174 MAPT 2009/4885HTR1D 4/4885LMNA 4625/4885
US-20010021777-A1 Indane or dihydroindole derivatives HTR4, GPR4, GPR174 MAPT 2009/4885HTR1D 4/4885LMNA 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.